2022年5月,美国临床内分泌医师学会(American Association of Clinical Endocrinology, AACE)及美国肝病研究学会(American Association for the Study of Liver Diseases, AASLD)颁布了基层医疗和内分泌临床实践中关于非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)的诊疗指南。该指南基于循证医学证据并对2010年至2021年间相关文献进行系统回顾,提出34条明确推荐意见,为成人及儿童NAFLD的诊断与治疗提供了规范性指导。该指南在问答行文模式的基础上,将关键信息转换为流程图,使内容更具逻辑性,便于临床推广运用。本文重点解读该指南的关键要素,聚焦亮点更新,并对NAFLD的规范性管理提出思考和建议。

[1] COTTER T G,RINELLA M.Nonalcoholic fatty liver disease 2020:the state of the disease[J].Gastroenterology,2020,158(7):1851-1864.
[2] CHEN Y Y,YEH M M.Non-alcoholic fatty liver disease:a review with clinical and pathological correlation[J].J Formos Med Assoc,2021,120(1 Pt 1):68-77.
[3] HARRISON S A,GAWRIEH S,ROBERTS K,et al.Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort[J].J Hepatol,2021,75(2):284-291.
[4] KANG S H,LEE H W,YOO J J,et al.KASL clinical practice guidelines:management of nonalcoholic fatty liver disease[J].Clin Mol Hepatol,2021,27(3):363-401.
[5] DUELL P B,WELTY F K,MILLER M,et al.Nonalcoholic fatty liver disease and cardiovascular risk:a scientific statement from the American Heart Association[J].Arterioscler Thromb Vasc Biol,2022,42(6):168-185.
[6] CHAN W K,TAN S S,CHAN S P,et al.Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease[J].J Gastroenterol Hepatol,2022,37(5):795-811.
[7] MCPHERSON S,ARMSTRONG M J,COBBOLD J F,et al.Quality standards for the management of non-alcoholic fatty liver disease(NAFLD):consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group[J].Lancet Gastroenterol Hepatol,2022,7(8):755-769.
[8] 中华医学会内分泌学分会,中华医学会糖尿病学分会.中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J].中华内分泌代谢杂志,2021,37(7):589-598.
[9] 中华医学会内分泌学分会.非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J].临床肝胆病杂志,2018,34(10):2103-2108.
[10] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗指南(基层医生版)[J].中西医结合肝病杂志,2019,29(5):483-486.
[11] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗指南(患者科普版)[J].中西医结合肝病杂志,2021,31(12):1153-1156.
[12] CUSI K,ISAACS S,BARB D,et al.American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings:co-sponsored by the American Association for the Study of Liver Diseases(AASLD)[J].Endocr Pract,2022,28(5):528-562.
[13] SCAPATICCI S,D'ADAMO E,MOHN A,et al.Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes[J].Front Endocrinol(Lausanne),2021,12:639548.
[14] GUO Z,LI M,HAN B,et al.Association of non-alcoholic fatty liver disease with thyroid function:a systematic review and metaanalysis[J].Dig Liver Dis,2018,50:1153-1162.
[15] KUMARENDRAN B,O'REILLY M W,MANOLOPOULOS K N,et al.Polycystic ovary syndrome,androgen excess,and the risk of nonalcoholic fatty liver disease in women:a longitudinal study based on a United Kingdom primary care database[J].PLoS Med,2018,15:e1002542.
[16] ADAMS L A,FELDSTEIN A,LINDOR K D,et al.Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction[J].Hepatology,2004,39:909-914.
[17] MINTZIORI G,POULAKOS P,TSAMETIS C,et al.Hypogonadism and non-alcoholic fatty liver disease[J].Minerva Endocrinol,2017,42(2):145-150.
[18] MESARWI O A,LOOMBA R,MALHOTRA A.Obstructive sleep apnea,hypoxia,and nonalcoholic fatty liver disease[J].Am J Respir Crit Care Med,2019,199:830-841.
[19] FUJII Y,NANASHIMA A,HIYOSHI M,et al.Risk factors for development of nonalcoholic fatty liver disease after pancreatoduodenectomy[J].Ann Gastroenterol Surg,2017,1:226-231.
[20] RAMOS A N,DE OLIVEIRA ROCHA B,DE ALMEIDA RÊGO V R,et al.The linkage between psoriasis and non-alcoholic fatty liver disease:a literature review[J].Acta Dermatovenerol Croat,2014,59(5):1772-1778.
[21] HONG H C,HWANG S Y,CHOI H Y,et al.Relationship between sarcopenia and nonalcoholic fatty liver disease:the Korean Sarcopenic Obesity Study[J].Hepatology,2014,59:1772-1778.
[22] CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2018,67(1):328-357.
[23] TACKE F,WEISKIRCHEN R.Non-alcoholic fatty liver disease(NAFLD)/non-alcoholic steatohepatitis(NASH)-related liver fibrosis:mechanisms,treatment and prevention[J].Ann Transl Med,2021,9(8):729.
[24] NEWSOME P N,BUCHHOLTZ K,CUSI K,et al.A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J].N Engl J Med,2021,384(12):1113-1124.
[25] 张学峰,杨光旭,朱友,等.NAFLD对大鼠葡萄糖、胰岛素代谢和肝糖原合成的影响[J].东南大学学报(医学版),2020,39(4):420-424.
[26] TAN Y,ZHEN Q,DING X,et al.Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes[J].Front Endocrinol(Lausanne),2022,13:935180.
[27] BELLANTI F,LO BUGLIO A,DOBRAKOWSKI M,et al.Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease[J].World J Gastroenterol,2022,28(26):3243-3257.
[28] CUSI K.Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes[J].Hepatology,2019,69(6):2318-2322.
[29] ATHYROS V G,BOUTARI C,STAVROPOULOS K,et al.Statins:an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk[J].Curr Vasc Pharmacol,2018,16(3):246-253.
[30] SANYAL A J,CHALASANI N,KOWDLEY K V,et al.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J].N Engl J Med,2010,362(18):1675-1685.
[31] 赵天慧,魏强,刘茜.非酒精性脂肪肝患者的受控衰减参数与脂代谢异常及颈动脉粥样硬化的关系[J].东南大学学报(医学版),2020,39(6):835-838.
[32] CUSI K,ORSAK B,BRIL F,et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus:a randomized trial[J].Ann Intern Med,2016,165(5):305-315.
[33] CUSI K.Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes[J].Diabetes Care,2020,43(2):275-279.